To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

Understanding the Mechanisms of Intravenous BCG-Induced Protection Against TB in NHP (TB Vaccine)

Two billion people worldwide are infected with Mycobacterium tuberculosis (Mtb) resulting in 10 million cases of clinical disease and 1.5 million deaths each year. The hurdles for developing a highly protective and durable vaccine against Mtb require addressing four central tenets of T cell immunology – magnitude, quality, breadth, and location of the response. These specific elements of the problem will be addressed by focusing on how altering the route of vaccination using a whole attenuated organism vaccine substantially increases immune responses and protection in a rigorous non-human primate model of Mtb infection.

Comprehensive Cellular Vaccine Immune Monitoring Consortium

A collaborative program that provides standardized and research level assays for clinical and pre-clinical HIV vaccine trials.

SHORTEN-TB

SHORTEN-TB will build on lessons learned from the HIT-TB program to identify leads that have the greatest potential to comprise drug regimens that will significantly reduce the duration of chemotherapy for tuberculosis.

PredictTB

PredictTB is a five-year clinical trial project that aims to shorten the treatment times of tuberculosis (TB) in drug-sensitive patients through individualized therapy.

The Dr. Franklin A. Neva Memorial Fund

The Dr. Franklin A. Neva Memorial Fund supports an annual lecture on a topic related to clinical tropical medicine and associated pathophysiology as part of the Laboratory of Parasitic Diseases’ (LPD) ongoing lecture series. It honors the legacy of Franklin A. Neva, M.D., a renowned virologist, parasitologist, clinician and former director of the Laboratory of Parasitic Diseases (LPD) at the National Institute of Allergy and Infectious Diseases (NIAID).

Plasticity and Mechanisms of Cognitive Remediation in Older Adults

Plasticity and Mechanisms of Cognitive Remediation in Older Adults supports a grant for a multicenter clinical research trial on remediating age-related cognitive decline through mindfulness-based stress reduction and exercise.

Roth Fellowship for CAEBV-HV Research

The Roth Fellowship for CAEBV-HV Research was established to support a fellowship in the lab of Jeffrey I. Cohen, M.D., Chief of the Laboratory of Infectious Diseases and Chief of the Medical Virology Section at the National Institute of Allergy and Infectious Diseases (NIAID). 

Accelerating Medicines Partnership: Rheumatoid Arthritis, Systemic Lupus Erythematosus & Related Autoimmune Disorders

Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus & Related Autoimmune Disorders is an initiative of the Accelerating Medicines Partnership (AMP), which is a multi-sector, pre-competitive  partnership among government, industry, and nonprofit organizations, the goal of which is to harness collective capabilities, scale and resources toward improving current efforts to develop new therapies for complex, heterogeneous diseases.

Support of Ebola Research by NIAID

In response to the critical Ebola Virus Disease (EVD) outbreak in 2014, the FNIH has established a fund that supports the Division of Clinical Research of the National Institute of Allergy and Infectious Diseases (NIAID) in its efforts to prevent, treat and research the EVD in West Africa.

Biomarkers Consortium - Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Clinical Endpoint Development (HABP/VABP)

The Biomarkers Consortium’s Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) Project aims to develop clinically relevant endpoints in clinical trials to improve antibacterial trial feasibility.